Seems uniquely good for rapid relief of depression/neuroplasticity
The genuinely interesting newer angle — ketamine alone, via neuronal synchrony. The 2024 Nature paper (Jiang-Xie / Kipnis lineage) used ketamine anesthesia specifically and argued the driver isn’t vascular pulsation but neurons: neural networks synchronize individual action potentials to create large-amplitude, rhythmic, self-perpetuating ionic waves in the interstitial fluid, and when they chemogenetically flattened those waves, cerebrospinal fluid infiltration into and clearance of molecules from the brain parenchyma was largely impeded. They picked ketamine precisely because it has been shown to enhance the glymphatic system at a level comparable to that in natural sleep. Their tagline — neurons that fire together “shower” together. This is a mechanistic claim that ketamine-induced synchronized neuronal activity drives clearance, and it’s somewhat independent of the xylazine confound since they used ketamine. I rate it plausible and interesting (~0.5–0.6) but note this whole convective-flow premise is contested — the same paper concedes the model has been challenged by the lack of a significant pressure gradient between para-arterial and paravenous spaces needed to drive convection. Nature + 3
The part nobody can answer well — sub-anesthetic / antidepressant-dose ketamine. This is probably what you actually care about, and it’s the biggest gap. Everything above is anesthetic dosing (~100 mg/kg in mice). The ketamine humans get in a depression clinic (~0.5 mg/kg infusion) or recreationally is a totally different pharmacological regime: low-dose ketamine increases glutamatergic activity, cortical arousal, gamma power — roughly the opposite of the high-delta, low-arousal slow-wave state that K/X produces and that the clearance literature keeps fingering as the driver. I could not find solid direct data on glymphatic flux under sub-anesthetic ketamine, and I’d flag this hard: extrapolating “K/X boosts mouse glymphatics” → “your ketamine infusion clears amyloid” is, on current evidence, unsupported and arguably backwards. My honest epistemic state here is “I don’t know,” not “I’m choosing between hypotheses” — there may be a paper I’m missing, but the mechanistic logic actively cuts against the naive extrapolation.
So, putting confidences on the table:
- Anesthetic K/X raises CSF influx in rodents — fairly likely (~0.8), but heavily xylazine-contaminated as a “ketamine” claim.
- K/X improves end-to-end clearance/efflux to lymphatics — genuinely contested (~0.4); at least one study shows reduced lymphatic drainage.
- Ketamine-driven neuronal synchrony mechanistically powers clearance — plausible (~0.5), resting on the still-disputed convection model.
- Sub-anesthetic/clinical ketamine enhances human glymphatic clearance — can’t support it; mechanism arguably points the other way. This is the claim to be most suspicious of if you see it asserted online.
The mode I’d collapse to if forced — “ketamine enhances glymphatic clearance” — is true-ish only in the narrow rodent-anesthesia, influx-measured, xylazine-confounded sense. The strongest counter, which I find pretty compelling, is that the result is really an α2-agonist + slow-wave-state result wearing a ketamine label, and it tells you little about ketamine as people actually encounter it.
What would sharpen this a lot: a study measuring glymphatic transport (ideally efflux, not just influx) under ketamine without xylazine at sub-anesthetic dose, awake or lightly sedated. If you’ve seen one, send it — that’s the missing keystone. Want me to dig specifically for human DTI-ALPS or ketamine-infusion glymphatic data?